Cambridge Trust’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $20.7M | Sell |
213,554
-86,496
| -29% | -$8.87M | 0.78% | 42 |
|
|
2023
Q4 | $30.3M | Sell |
300,050
-3,121
| -1% | -$301K | 1.26% | 25 |
|
|
2023
Q3 | $30.9M | Sell |
303,171
-4,750
| -2% | -$482K | 1.42% | 19 |
|
|
2023
Q2 | $31.1M | Sell |
307,921
-2,593
| -0.8% | -$259K | 1.41% | 22 |
|
|
2023
Q1 | $28.6M | Sell |
310,514
-2,350
| -0.8% | -$205K | 1.36% | 23 |
|
|
2022
Q4 | $28.4M | Buy |
312,864
+24,046
| +8% | +$2.03M | 1.27% | 28 |
|
|
2022
Q3 | $22M | Sell |
288,818
-2,404
| -0.8% | -$199K | 1.04% | 32 |
|
|
2022
Q2 | $24.6M | Buy |
291,222
+12,158
| +4% | +$1.07M | 1.08% | 29 |
|
|
2022
Q1 | $24.5M | Buy |
279,064
+6,086
| +2% | +$527K | 0.86% | 39 |
|
|
2021
Q4 | $23.9M | Sell |
272,978
-20,590
| -7% | -$1.71M | 0.77% | 46 |
|
|
2021
Q3 | $24M | Buy |
293,568
+182,675
| +165% | +$16.4M | 0.91% | 44 |
|
|
2021
Q2 | $10.1M | Buy |
110,893
+2,992
| +3% | +$266K | 0.38% | 76 |
|
|
2021
Q1 | $9.22M | Buy |
107,901
+2,019
| +2% | +$181K | 0.38% | 76 |
|
|
2020
Q4 | $10M | Buy |
105,882
+2,193
| +2% | +$192K | 0.47% | 60 |
|
|
2020
Q3 | $9.02M | Buy |
103,689
+615
| +0.6% | +$53.3K | 0.47% | 61 |
|
|
2020
Q2 | $8.67M | Buy |
103,074
+2,455
| +2% | +$212K | 0.46% | 61 |
|
|
2020
Q1 | $8.3M | Buy |
100,619
+1,597
| +2% | +$142K | 0.57% | 53 |
|
|
2019
Q4 | $9.38M | Buy |
99,022
+1,816
| +2% | +$163K | 0.5% | 69 |
|
|
2019
Q3 | $8.45M | Buy |
97,206
+25
| +0% | +$2.25K | 0.49% | 68 |
|
|
2019
Q2 | $8.87M | Sell |
97,181
-39,337
| -29% | -$3.33M | 0.51% | 64 |
|
|
2019
Q1 | $11.8M | Buy |
136,518
+4,786
| +4% | +$384K | 0.7% | 53 |
|
|
2018
Q4 | $10.1M | Buy |
131,732
+10,587
| +9% | +$824K | 0.7% | 49 |
|
|
2018
Q3 | $9.35M | Sell |
121,145
-4,313
| -3% | -$319K | 0.54% | 62 |
|
|
2018
Q2 | $8.49M | Sell |
125,458
-2,988
| -2% | -$206K | 0.53% | 61 |
|
|
2018
Q1 | $9.31M | Buy |
128,446
+2,607
| +2% | +$198K | 0.59% | 58 |
|
|
2017
Q4 | $9.47M | Sell |
125,839
-3,847
| -3% | -$290K | 0.6% | 56 |
|
|
2017
Q3 | $9.98M | Buy |
129,686
+10,320
| +9% | +$779K | 0.67% | 51 |
|
|
2017
Q2 | $8.93M | Buy |
119,366
+57,966
| +94% | +$4.11M | 0.62% | 53 |
|
|
2017
Q1 | $4.09M | Sell |
61,400
-14,171
| -19% | -$944K | 0.27% | 89 |
|
|
2016
Q4 | $4.93M | Sell |
75,571
-182,900
| -71% | -$11.9M | 0.35% | 73 |
|
|
2016
Q3 | $18.3M | Buy |
258,471
+8,798
| +4% | +$641K | 1.34% | 26 |
|
|
2016
Q2 | $18.5M | Buy |
249,673
+108,575
| +77% | +$7.5M | 1.41% | 22 |
|
|
2016
Q1 | $9.16M | Sell |
141,098
-4,973
| -3% | -$338K | 0.75% | 51 |
|
|
2015
Q4 | $11.3M | Sell |
146,071
-2,735
| -2% | -$217K | 0.92% | 46 |
|
|
2015
Q3 | $12.3M | Buy |
148,806
+135,069
| +983% | +$12M | 1.07% | 39 |
|
|
2015
Q2 | $1.21M | Sell |
13,737
-5,508
| -29% | -$505K | 0.1% | 109 |
|
|
2015
Q1 | $1.7M | Sell |
19,245
-560
| -3% | -$49.7K | 0.14% | 98 |
|
|
2014
Q4 | $1.65M | Sell |
19,805
-170
| -0.9% | -$14.1K | 0.14% | 97 |
|
|
2014
Q3 | $1.68M | Sell |
19,975
-115
| -0.6% | -$9.3K | 0.15% | 90 |
|
|
2014
Q2 | $1.63M | Sell |
20,090
-469
| -2% | -$36.9K | 0.14% | 94 |
|
|
2014
Q1 | $1.57M | Sell |
20,559
-249
| -1% | -$18.1K | 0.14% | 92 |
|
|
2013
Q4 | $1.5M | Sell |
20,808
-145
| -0.7% | -$10.1K | 0.14% | 94 |
|
|
2013
Q3 | $1.44M | Sell |
20,953
-536
| -2% | -$35.5K | 0.14% | 93 |
|
|
2013
Q2 | $1.36M | Buy |
+21,489
| New | +$1.4M | 0.14% | 91 |
|
Other funds holding NVS
Cambridge Trust's NVS Position: Q1 2024 in Review
Cambridge Trust reduced its Novartis (NVS) stake by 29% in Q1 2024, selling an estimated $8.87M and leaving 213,554 shares worth $20.7M. The position accounts for 0.78% of the portfolio, ranked #42.
Cambridge Trust first reported a position in NVS in Q2 2013 and has held it in 44 quarters since. The position peaked at $31.1M in Q2 2023. 1,253 funds tracked by Wall St. Rank hold NVS as of Q1 2024.
- Cambridge Trust held 213,554 shares of Novartis worth $20.7M as of Q1 2024.
- Cambridge Trust sold 86,496 Novartis shares in Q1 2024, an estimated $8.87M.
- Novartis made up 0.78% of Cambridge Trust's portfolio in Q1 2024, its #42 holding.
- Cambridge Trust first reported a position in Novartis in Q2 2013 and has held it in 44 quarters since.
- Cambridge Trust's Novartis position peaked at $31.1M in Q2 2023.
- 1,253 funds tracked by Wall St. Rank held Novartis as of Q1 2024.
Based on Cambridge Trust's 13F filing for Q1 2024, filed 30 May 2024.